IDEAYA Biosciences (IDYA) Expected to Announce Quarterly Earnings on Thursday

IDEAYA Biosciences (NASDAQ:IDYA) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect IDEAYA Biosciences to post earnings of ($1.03) per share and revenue of $5.9460 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 13, 2026 at 12:30 PM ET.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 EPS for the quarter, topping the consensus estimate of ($0.12) by $1.45. The company had revenue of $207.83 million during the quarter, compared to the consensus estimate of $59.98 million. On average, analysts expect IDEAYA Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

IDEAYA Biosciences Price Performance

IDYA opened at $33.28 on Thursday. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $39.28. The company has a 50 day simple moving average of $34.91 and a two-hundred day simple moving average of $29.92. The firm has a market cap of $2.92 billion, a P/E ratio of -17.89 and a beta of 0.10.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC lifted its holdings in shares of IDEAYA Biosciences by 345.2% in the 1st quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock worth $8,970,000 after acquiring an additional 424,625 shares during the last quarter. Balyasny Asset Management L.P. raised its position in IDEAYA Biosciences by 1,619.5% in the 3rd quarter. Balyasny Asset Management L.P. now owns 380,311 shares of the company’s stock worth $10,348,000 after purchasing an additional 358,194 shares during the period. Dimensional Fund Advisors LP raised its position in IDEAYA Biosciences by 191.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 497,048 shares of the company’s stock worth $13,525,000 after purchasing an additional 326,376 shares during the period. UBS Group AG boosted its position in shares of IDEAYA Biosciences by 40.5% during the third quarter. UBS Group AG now owns 1,056,577 shares of the company’s stock valued at $28,749,000 after buying an additional 304,672 shares during the period. Finally, Soleus Capital Management L.P. purchased a new position in shares of IDEAYA Biosciences during the second quarter valued at approximately $5,255,000. Institutional investors own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Royal Bank Of Canada boosted their price objective on IDEAYA Biosciences from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Mizuho boosted their target price on shares of IDEAYA Biosciences from $44.00 to $46.00 and gave the stock an “outperform” rating in a report on Tuesday, November 11th. Truist Financial lifted their price target on shares of IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. BTIG Research reissued a “buy” rating and set a $62.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Finally, The Goldman Sachs Group raised their price target on IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, October 21st. Fifteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $46.60.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.